GlassScriptPhysician profile
Yusuf Azim
NPI 1275995797
$2,945.80
in general payments reported to CMS, 2019-2025
19 companies · $813 in 2025
The $813 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,024 · 2022: $198 · 2023: $27.48 · 2024: $883 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $531.81 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $409.75 | 2021-2024 | Spravato |
| Abbvie INC. | $379.78 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $368.80 | 2021-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $275.66 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $173.61 | 2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $158.13 | 2024 | Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $142.17 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $107.72 | 2021-2025 | Aplenzin |
| Tris Pharma INC | $87.46 | 2024-2025 | Dyanavel Xr |
| Corium, LLC | $66.26 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $57.37 | 2025 | Auvelity |
| Alkermes, INC. | $54.96 | 2025 | Aristada, Lybalvi |
| Lundbeck LLC | $37.37 | 2021 | |
| Allergan, INC. | $21.79 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $21.69 | 2025 | |
| Collegium Pharmaceutical, INC. | $18.15 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $16.90 | 2025 | Relexxii |
| Adlon Therapeutics L.P. | $16.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusuf Azim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.